Akero Therapeutics Inc

Akero Therapeutics — Investor Presentation (May 2021)

46 slides from Akero Therapeutics's investor presentation, May 13, 2021

  1. Slide 1: A Global Disease, A Pioneering Treatment

    A Global Disease, A Pioneering Treatment Corporate Presentation May 2021

  2. Slide 2: Corporate Highlights

    CORPORATE HIGHLIGHTS - CONFIDENTIAL -

  3. Slide 3: Extensive Development and Commercialization Experience Involved in 20+ Medicine Approvals

    EXTENSIVE DEVELOPMENT AND COMMERCIALIZATION EXPERIENCE INVOLVED IN 20+ MEDICINE APPROVALS Andrew Cheng, MD, PhD | President & CEO 19 years at Gilead Chief Medical Officer & HIV Division Head Major role in 11 NDA/MAA approvals Jonathan Young, PhD, JD | Founder, EVP & COO Over 15 years in biotechnolog

  4. Slide 4: NASH: A Serious and Debilitating Multi-System Disease

    NASH: A SERIOUS AND DEBILITATING MULTI-SYSTEM DISEASE NASH epidemic fueled by rise in obesity and diabetes No treatments currently available An estimated 17 million Americans have NASH, with expectation that population will grow >50% by 2030 The number of NASH patients with advanced-stage fibrosis a

  5. Slide 5: Cirrhotic NASH Patients Have Poor Prognosis

    CIRRHOTIC NASH PATIENTS HAVE POOR PROGNOSIS Liver-related mortality rate increases substantially from F3 to F4 fibrosis ~60% 5-year mortality for F4 NASH patients absent transplant Fibrosis Stage Survival Free of Liver Transplantation 0 0 Cumulative Survival (%) Rate (per 1,000 PYF) 15 10 5 0 F0F1F2

  6. Slide 6: EFX Engineering Potentially Optimal for NASH Efficacy, With Convenient Once-Weekly Dosing

    EFX ENGINEERING POTENTIALLY OPTIMAL FOR NASH EFFICACY, WITH CONVENIENT ONCE-WEEKLY DOSING Key attributes Akero proprietary Fc-FGF21, Point mutations Increases half-life from < 2 hours to 3-4 days High affinity for β-Klotho Better translation to human pharmacology Balanced potency at FGFR1c, 2c, 3c I

  7. Slide 7: EFX Acts on Two Major Sources of Liver Fat

    EFX ACTS ON TWO MAJOR SOURCES OF LIVER FAT WITH POTENTIAL FOR OPTIMAL REDUCTION Sources of Fat Flowing into and Through Liver for NASH Patients Acting on both hepatic and peripheral sources of liver fat is key to optimizing liver fat reduction Dietary Fat (10-20%) Liver: De Novo Lipogenesis (30-40%)

  8. Slide 8: EFX Direct and Indirect Anti-Fibrotic Effects

    EFX DIRECT AND INDIRECT ANTI-FIBROTIC EFFECTS Kupffer Cell Activation Hepatocyte Stress & Death Direct EffectIndirect Effect Fibrosis - CONFIDENTIAL - *Cited literature available on company website 8

  9. Slide 9: Phase 2a Trial (BALANCED) Design (F1-F3 NASH)

    PHASE 2A TRIAL (BALANCED) DESIGN (F1-F3 NASH) 28mg EFX (n=20) Placebo (n=20) Screening Biopsy-Confirmed NASH Randomization Safety Follow-Up Responder Paired Biopsies Primary Endpoint Absolute Liver Fat 70mg EFX (n=20) 50mg EFX (n=20) Key Secondary Endpoints Relative Liver Fat Response Rate ALT Key E

  10. Slide 10: Phase 2a Expansion Cohort C Trial Design (F4 NASH)

    PHASE 2A EXPANSION COHORT C TRIAL DESIGN (F4 NASH) Screening Randomization Primary Endpoint Safety & tolerability 16 Weeks Placebo (n=10) EFX 50 mg (n=20) Liver Biopsy FibroScan Fibrosis Biomarkers (ELF, Pro-C3) * * Protocol amended to include voluntary end-of-treatment biopsies - CONFIDENTIAL -

  11. Slide 11: Baseline Demographics: Main Study & Cohort C

    BASELINE DEMOGRAPHICS: MAIN STUDY & COHORT C a Full Analysis Set, F1-F3 (all subjects randomized into the BALANCED main study); b Full Analysis Set, F4 (all subjects randomized into BALANCED Cohort C [except where - CONFIDENTIAL - 11

  12. Slide 12: High Rates of Fibrosis Improvement Across All Dose Groups (F1-F3 NASH)

    HIGH RATES OF FIBROSIS IMPROVEMENT AFTER 16 WEEKS ACROSS ALL DOSE GROUPS (F1-F3 NASH) 48% 0% 19 Biopsy Reading biopsies were centrally read by a single NASH-CRN pathologist Baseline biopsies were not re-read with end-of-treatment biopsies All biopsies were read blinded to both treatment assignment a

  13. Slide 13: Fibrosis Improvement in F2-F3 Patients: Half Improved 2 Stages

    FIBROSIS IMPROVEMENT IN F2-F3 PATIENTS: HALF OF PATIENTS IMPROVED 2 STAGES All EFX Patients (n=40) Baseline F2-F3 EFX Patients (n=22) 68% 23% 9% Change in liver fibrosis Improved No Change 68% 2-Stage Improvement (n=11, 50%) 1-Stage Improvement (n=4, 18%) 35% Worsened 23% 10%9% - CONFIDENTIAL -

  14. Slide 14: High Rate of Fibrosis Improvement Among Cirrhotic Patients (F4 NASH)

    HIGH RATE OF FIBROSIS IMPROVEMENT AFTER ONLY 16 WEEKS AMONG CIRRHOTIC PATIENTS (F4 NASH) 33% 0% 4 Biopsy Reading All baseline and end-of-treatment biopsies were read by a single NASH-CRN pathologist All biopsies were read blinded to both treatment assignment and patient Baseline biopsies were read i

  15. Slide 15: Rapid Improvements in Fibrosis Biomarkers (F1-F3 NASH)

    RAPID IMPROVEMENTS IN FIBROSIS BIOMARKERS CONSISTENT WITH HISTOLOGICAL IMPROVEMENTS (F1-F3 NASH) Pro-C3, LS Mean Change from Baseline Pro-C3, LS Mean (ug/L) 10% 0% -10% BLW1W4W8W12 -20% -30% -40% -50% Dose Group Baseline Δ Week 12 Placebo 16.1 -1.5 28mg 19.2 -6.1*** 50mg 16.2 -5.9*** 70mg 17.2 -6.7*

  16. Slide 16: Improvements in Fibrosis Biomarkers in Cirrhotic NASH Patients (F4 NASH)

    IMPROVEMENTS IN FIBROSIS BIOMARKERS IN CIRRHOTIC NASH PATIENTS SUPPORT HISTOLOGY RESULTS (F4 NASH) LS Mean Change From Baseline to Week 16 Liver Stiffness1 (kPa) 0 -1 -1.9 -2 -3 -4 -5 -5.7†† -6 PlaceboEFX 50mg n=10n=20 Pro-C3 (µg/L) 0 -2 -3.4 -4 -6 -8 -9.0* -10 PlaceboEFX 50mg n=10n=20 ELF Score 0.3

  17. Slide 17: Interpreting the Rapid Reversal of Fibrosis Observed in NASH Patients Treated with EFX

    INTERPRETING THE RAPID REVERSAL OF FIBROSIS OBSERVED IN NASH PATIENTS TREATED WITH EFX ↓ Inflammation↓ Liver fat ↓ Collagen Synthesis ↓ Hepatocyte Stress Directly anti-fibrotic Indirectly anti-fibrotic EFX Fibrosis reversal in cirrhotic patients (F4), two-stage improvement of fibrosis in F2/F3 patie

  18. Slide 18: Substantial Reductions in Liver Fat Across All Dose Groups (F1-F3 NASH)

    SUBSTANTIAL REDUCTIONS IN LIVER FAT AT WEEK 12 ACROSS ALL DOSE GROUPS (F1-F3 NASH) MRI-PDFF Images for Patient Treated with 50mg EFX Baseline 22.2% Liver Fat Week 12 2.0% Liver Fat (↓90%) Proton Density Fat Fraction (PDFF) Analyzed with LiverMultiScan LS Mean Reduction in Liver Fat Placebo 28mg 50mg

  19. Slide 19: Substantial Reductions in Markers of Liver Injury (F1-F3 NASH)

    SUBSTANTIAL REDUCTIONS IN MARKERS OF LIVER INJURY AFTER 16 WEEKS OF TREATMENT (F1-F3 NASH) ALT, LS Mean Change from Baseline AST, LS Mean Change from Baseline 40% BL W1W4W8W12W16W20 40% BL W1W4W8W12W16W20 20% 20% 0%0% -20% -40% -60% *** *** *** *** *** *** *** *** *** ** ** *** -20% -40% -60% *** **

  20. Slide 20: High Response Rates on NASH Resolution (F1-F3 NASH)

    HIGH RESPONSE RATES ON NASH RESOLUTION AFTER 16 WEEKS ACROSS ALL DOSE GROUPS (F1-F3 NASH) NASH Resolution1,2 and No Worsening of Fibrosis 70% 60% 54% 50%46%43% 40% 30% 676 10% 0% Placebo N=2 All EFX N=40 28mg N=13 50mg N=13 70mg N=14 2 Secondary and exploratory histological endpoints were not powere

  21. Slide 21: NASH Resolution Also Observed in Cirrhotic Patients (F4 NASH)

    NASH RESOLUTION ALSO OBSERVED IN CIRRHOTIC PATIENTS (F4 NASH) NASH Resolution1,2 30% 20% 10% 0% Placebo n=5 EFX 50mg n=12 25% 0% ≥2 Point NAS Reduction 1 NAS score of 0 or 1 for lobular inflammation and a score of 0 for ballooning 2 Study not powered to assess statistical significance of histologica

  22. Slide 22: Drug-Related Treatment-Emergent Adverse Events (F1-F3 NASH)

    DRUG-RELATED TREATMENT-EMERGENT ADVERSE EVENTS (TEAE) (F1-F3 NASH) *Across EFX dose groups a Muscular Weakness & Myalgia; b Nausea, Vomiting & Dysgeusia; Panic Attack and Anxiety-Linked Tremor; c Dysphagia (Not Drug Related); Acute Pancreatitis (also an SAE); Vomiting; Fatigue & Nausea; d Related to

  23. Slide 23: Tolerability Overview (F4 NASH)

    TOLERABILITY OVERVIEW (F4 NASH) Most Frequent (>15%) Drug-Related AEs Placebo (N=10) EFX 50mg (N=17) Diarrhea 1 (10%) 7 (41%) Nausea 1 (10%) 5 (29%) Injection site reaction 0 5 (29%) Injection site erythema 0 4 (24%) Headache 0 3 (18%) TEAE/SAE Disposition Placebo EFX 50mg Study Discontinuations 1a

  24. Slide 24: Weight Loss Observed for All Dose Groups (F1-F3 NASH)

    WEIGHT LOSS OBSERVED FOR ALL DOSE GROUPS (F1-F3 NASH) Mean Change in Body Weight (kg) BL W1 W4 W8 W12 W16 0 -1 -2 -3 -4 Placebo 28mg 50mg 70mg Mean Change in Body Weight at Week 16 (kg) +0.1 0 -1 -0.3 -2 -2.3 -3 -3.7 -4 Placebo28mg 50mg 70mg - CONFIDENTIAL -

  25. Slide 25: Improved Lipoprotein Profile (F1-F3 NASH)

    IMPROVED LIPOPROTEIN PROFILE (F1-F3 NASH) LS Mean Change From Baseline to Week 16 (%) Triglycerides 10% 0% -10% +6% -20% -30% -40% -39% *** -48% -46% -50% *** Placebo 28mg50mg *** 70mg HDL Cholesterol 50% 40% *** *** +39% +41% 30% *** +34% 20% 10% +4% 0% Placebo 28mg50mg70mg Non-HDL Cholesterol 0% -

  26. Slide 26: Clinically Meaningful Improvements in Glycemic Control After 16 Weeks (F1-F3 NASH)

    CLINICALLY MEANINGFUL IMPROVEMENTS IN GLYCEMIC CONTROL AFTER 16 WEEKS (F1-F3 NASH) LS Mean Change From Baseline to Week 16 (%) Type 2 DM Patients (N=41) 0.1 0.0 -0.1 -0.2 -0.3 -0.4 -0.5 -0.6 -0.7 -0.8 -0.9 +0.0 +0.1 -0.6 Placebo 28mg50mg -0.9 ** 70mg HbA1c1 Type 2 DM Patients (N=41) 20% 10% 0% -10%

  27. Slide 27: NASH Development Landscape: Fibrosis Improvement (F1-F3)

    NASH DEVELOPMENT LANDSCAPE: FIBROSIS IMPROVEMENT (F1-F3) Proportion of Subjects with ≥1 Stage Improvement in Fibrosis and No Worsening of NAS1 Efruxifermin 16 Wks (Ph2a) Weekly Injection Lanifibranor 24 Wks (Ph2b) Daily Oral Aldafermin 24 Wks (Ph2a) Daily Injection Resmetirom 36 Wks (Ph2a) Daily Ora

  28. Slide 28: Cohort C Results in Context: Fibrosis Improvement (F4)

    COHORT C RESULTS IN CONTEXT: FIBROSIS IMPROVEMENT* (F4) Fc-FGF21 GAL-3 Efruxifermin 16 Wks (Ph2a) SC Injection ASK-1 Selonsertib ACC Firsocostat FXR Cilofexor Belapectin 52 Wks (Ph2b) Oral LOXL2 Simtuzumab 48 Wks Increasing dosing duration 96 Wks 13 13 14 14 15 14 13 7 8 8 5 Pbo6mg18mg (n=172)(n=351

  29. Slide 29: NASH Development Landscape: NASH Resolution (F1-F3)

    NASH DEVELOPMENT LANDSCAPE: NASH RESOLUTION (F1-F3) Proportion of Subjects with Resolution of NASH and No Worsening of Fibrosis1 Efruxifermin 16 Wks (Ph2a) Weekly Injection Lanifibranor 24 Wks (Ph2b) Daily Oral Aldafermin 24 Wks (Ph2a) Daily Injection Resmetirom 36 Wks (Ph2a) Daily Oral Seladelpar 5

  30. Slide 30: Next Steps for EFX: Parallel 2b Trials in F2/F3 & F4

    NEXT STEPS FOR EFX: PARALLEL 2B TRIALS IN F2/F3 & F4 Phase 2aPhase 2b F1-F3 F4 F2/F3 F4 - CONFIDENTIAL -

  31. Slide 31: Phase 2b (F2/F3) Trial Design (HARMONY)

    PHASE 2B (F2/F3) TRIAL DESIGN (HARMONY) Key Inclusion Criteria F2-3 NASH NAS ≥4 Liver fat ≥8% Phase 2b Primary Endpoint Fibrosis Improvement Key Secondary Efficacy Endpoints NASH Resolution Fibrosis Markers Lipoproteins Glycemic Control• Liver Injury Weight Change MRI-PDFF Markers EFX* EFX 28mg EFX

  32. Slide 32: Strong Financial Position

    STRONG FINANCIAL POSITION COMPLETED UPSIZED FOLLOW-ON OFFERING July 10 , 2020 ~$106M Raised in aggregate gross proceeds ~$216M Raised in aggregate gross proceeds ~$250M Current cash, cash equivalents and marketable securities are expected to be sufficient to fund current operating plan into the thir

  33. Slide 33: Consistent Record of Milestone Delivery

    CONSISTENT RECORD OF MILESTONE DELIVERY Amgen License $45M Series A June $45.5M Series B December ~$106M Upsized IPO June BALANCED Initiation July BALANCED F1-F3 MRI-PDFF Read-out March BALANCED F1-F3 Liver Biopsy Read-out June ~$216M Upsized Offering July HARMONY F2/F3 Ph2b Initiation February BALA

  34. Slide 34: Backup Slides

    Backup Slides

  35. Slide 35: BALANCED Main Study Patient Disposition

    Randomized (80) Randomized Not Dosed EFX (1) Dosed (79) Week 12 MRI-PDFF (68) Non-Responders Placebo (18) MRI-PDFF Responders (50) (≥ 30% Relative Reduction) Biopsies Not Collected Due to COVID-19 EFX (8) - CONFIDENTIAL -

  36. Slide 36: Cohort C Patient Disposition

    Randomized/Dosed (n=30) Confirmed F4 (n=27 ) Not Confirmed F4 by central reader (3) Discontinued (2) Withdrawn Consent Placebo (1) Due to AEs EFX(1) Did not consent to end-of-treatment biopsy (8) - CONFIDENTIAL -

  37. Slide 37: Magnitude of Liver Fat Reduction (F1-F3 NASH)

    MAGNITUDE OF LIVER FAT REDUCTION (F1-F3 NASH) 1 A single placebo responder lost 25 pounds over 16 weeks (11% weight reduction) - CONFIDENTIAL - Source Data: MRI-PDFF Evaluable Analysis Set (all BALANCED main study subjects who had baseline and Week 12 MRI-PDFF37

  38. Slide 38: Expanding EFX to Cirrhotic Patient Population (F4)

    EXPANDING EFX TO CIRRHOTIC PATIENT POPULATION (F4) Developing Treatments for Cirrhotic (F4) NASH FDA draft guidance specific for F4 patients Projected ~3.5M US F4 patients in 2030 FDA: The goals of treatment for compensated NASH cirrhosis are to halt or slow progression of fibrosis, prevent clinical

  39. Slide 39: Cirrhosis Regression Is Associated with Improved Clinical Outcomes

    CIRRHOSIS REGRESSION IS ASSOCIATED WITH IMPROVED CLINICAL OUTCOMES Pooled treatment groups from STELLAR 4 and simtuzumab cirrhosis study Hazard Ratio: 0.16 p=0.0104 7.2 69/957 1.1 2/176 69/834 0.7 2/300 Liver-related events (%) 6 5 4 3 1 0 Hazard Ratio: 0.08 p=0.0004 8.3 No fibrosis regression Fibro

  40. Slide 40: Reductions in Markers of Liver Injury (F4 NASH)

    REDUCTIONS IN MARKERS OF LIVER INJURY (F4 NASH) LS Mean Change from Baseline to Week 16 ALT (U/L) 0 -2 -1.3 -4 -6 -8 -10.3** -10 PlaceboEFX 50mg n=10n=20 AST (U/L) 0 -2 -4.5 -4 -6 -8 -9.6††† -10 PlaceboEFX 50mg n=10n=20 ** p<0.01, versus placebo (ANCOVA) ††† p<0.001, versus baseline (ANCOVA) - CONFI

  41. Slide 41: Improved Lipoprotein Profile (F4 NASH)

    IMPROVED LIPOPROTEIN PROFILE (F4 NASH) LS Mean Change From Baseline to Week 16 (%) LDL Cholesterol 20% 15% +16% 10% 5% 0% -5% -8% Triglycerides 10% 5% 0% -5% -10% -15% -20% -25% -30% +1% -29% ** HDL Cholesterol 35% 30% ** +33% 25% 20% 15% 10% 5% +3% Non-HDL Cholesterol 15% 10% 5% 0% -5% -10% -15% +1

  42. Slide 42: Improved Glycemic Control; Trend Toward Weight Loss (F4 NASH)

    IMPROVED GLYCEMIC CONTROL; TREND TOWARD WEIGHT LOSS (F4 NASH) LS Mean Change From Baseline to Week 16 (%) HbA1c1 0.3 0.2 +0.1 0.1 0.0 -0.1 -0.2 -0.3 -0.4 -0.4 ** -0.5 PlaceboEFX 50mg n=10n=20 Adiponectin2 100% *** +95% 75% 50% 25% +4% 0% PlaceboEFX 50mg n=10n=20 C-Peptide2 0% -5% -7% -10% -15% -20%

  43. Slide 43: FGF21 Development Landscape

    FGF21 DEVELOPMENT LANDSCAPE Note: These data are derived from different clinical trials at different points in time, with differences in trial design and patient populations. No head-to-head clinical trials have been conducted. NR, not reported Sanyal et al (2019) Lancet; 89Bio October 5 Corporate P

  44. Slide 44: Change from Baseline to End of Study

    Change from Baseline to End of Study Change from Baseline to End of Study Adiponectin 100% 80% 60% 40% 20% 0% -20% pbo2850 QW QW EFX (Akero) pbo 1020 QD QW BMS pbo 182736 QW QW Q2W 89Bio* Triglycerides 10% 0% -10% -20% -30% -40% -50% pbo2850 QW QW EFX (Akero) pbo 1020 QD QW BMS pbo 182736 QW QW Q2W

  45. Slide 45: FGF21 Development Landscape: Summary

    FGF21 DEVELOPMENT LANDSCAPE: SUMMARY - CONFIDENTIAL -

  46. Slide 46: A Global Disease, A Pioneering Treatment

    A Global Disease, A Pioneering Treatment NASDAQ: AKRO

Akero Therapeutics — Investor Presentation (May 2021) on 6ix